Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
4 minute read
  • Biotech
  • FDA
  • General
  • IPOs
  • News
  • Penny Stocks
  • Small Cap

The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts

By Shanthi Rexaline
Today, 3:31 AM
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10)

ALKS

Read More
2 minute read
  • FDA
  • News

Gilead Sciences Says FDA Approved New Formulation Of Epclusa, Expanding Pediatric Indication To Treat Children Ages 3 And Older With Chronic Hepatitis C

By Benzinga Newsdesk
Today, 3:31 AM
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of the pediatric indication of Epclusa® (sofosbuvir/velpatasvir) for the treatment

GILD

Read More
1 minute read
  • Media
  • Trading Ideas

‘Halftime Report’ Traders Share Their Thoughts On Gilead, IBM And More

By Craig Jones
Today, 3:31 AM
On CNBC's "Fast Money Halftime Report," Josh Brown said ICICI Bank Ltd (NYSE: IBN) looks like it's going higher.

ABBV

Read More
11 minute read
  • FDA
  • News

Gilead Says Co’s Kite’s Tecartus Demonstrates ‘High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation’

By Benzinga Newsdesk
Today, 3:31 AM
Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation -- 71% of Adult Patients in Phase 2 ZUMA-3

GILD

Read More
1 minute read
Uncategorized

‘Fast Money’ Traders Weigh In On IBB And Gilead

By Craig Jones
Today, 3:31 AM
On CNBC's "Fast Money," Tim Seymour spoke about a possible break out in iShares Nasdaq Biotechnology ETF (NASDAQ: IBB).

AMGN

Read More
2 minute read
Uncategorized

Dogecoin Fulfills ‘Doge Day’ Goal Of 69 Cents Weeks Later, Surpasses Snapchat, GM In Valuation

By Shivdeep Dhaliwal
Today, 3:31 AM
The joke cryptocurrency Dogecoin (DOGE) touched a fresh all-time high in the early hours of Wednesday, crossing the much sought-after 69 cent mark.

FDX

Read More
4 minute read
Uncategorized

9 Health Care Stocks Showing Unusual Options Activity In Today’s Session

By Benzinga Insights
Today, 3:31 AM
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to hyperbolic or underperforming levels.

ABBV

Read More
2 minute read
Uncategorized

15 Stocks Moving In Thursday’s After-Hours Session

By Tyree Gorges
Today, 3:31 AM
Gainers Amazon (NASDAQ: AMZN) shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. The company also issued Q2 sales guidance above estimates.

AMZN

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Top Stories
  • Trading Ideas

7 Blockbuster Drugs Expected To Be Launched In 2020

By Shanthi Rexaline
Today, 3:31 AM
Biotech stocks had a fairly decent run in 2019, thanks to record deal flow, several path-breaking innovation in…

AIMT

Posts navigation

Previous 1 … 31 32
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service